Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Strategy

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

Expects to file with the FDA next year

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

- PMLiVE

Gracell Bio developing faster, cheaper CAR-T production

Manufacturing can be cut from two weeks to one day

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

The first, my last, my everything

The inescapable rise of patient-centricity

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links